Stephen M. Ansell

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 52 papers. Top paper: “Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies”.

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3706

N/A

4.4DataRank · unranked

198 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more

Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sézary syndrome

American Journal of Hematology(2011)10.1002/ajh.21960

N/A

3.7DataRank · unranked

56 citations

Ryan A. Wilcox, Susan M. Harrington, Eugene D. Kwon, Stephen M. Ansell, Nneka I. Comfere +1 more

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30221-0

N/A

3.3DataRank · unranked

142 citations

Fangxin Hong, Richard F. Ambinder, Jonathon B. Cohen, Michael J. Robertson, Kevin A. David +12 more

Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.05.004

N/A

2.0DataRank · unranked

66 citations

Amylou C. Dueck, Gita Thanarajasingam, Joan M. Griffin, Carrie A. Thompson, Urshila Durani +12 more

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Blood(2022)10.1182/blood.2022015851

N/A

1.1DataRank · unranked

1538 citations

Elaine S. Jaffe, James R. Cook, Leticia Quintanilla‐Martínez, Steven H. Swerdlow, Kenneth C. Anderson +68 more

A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1345

N/A

0.851DataRank · unranked

22 citations

Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig +11 more

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

Leukemia(2021)10.1038/s41375-021-01193-6

N/A

0.665DataRank · unranked

83 citations

Luca Castagna, Laura Giordano, Vincent T. Ho, Paolo Corradini, Anna Guidetti +61 more

Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma

Blood Cancer Journal(2021)10.1038/s41408-021-00521-4

N/A

0.631DataRank · unranked

66 citations

Angelo Famà, Melissa C. Larson, Andrew L. Feldman, José C. Villasboas, Zhi-Zhang Yang +20 more

Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation

Nature Communications(2024)10.1038/s41467-024-50830-y

N/A

0.622DataRank · unranked

17 citations

Kerstin Wenzl, C. Chris Huang, María Ortiz, Chih-Chao Hsu, Matthew J. Maurer +23 more

Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May HarborMYD88L265P Mutations

American Journal of Clinical Pathology(2016)10.1093/ajcp/aqw072

N/A

0.604DataRank · unranked

55 citations

Wilson I. Gonsalves, Stephen M. Ansell, Patricia T. Greipp, Lori A. Frederick, David S. Viswanatha +7 more

Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia

Blood Cancer Discovery(2021)10.1158/2643-3230.bcd-21-0043

N/A

0.538DataRank · unranked

35 citations

Ajay K. Nooka, Allison R. Carr, Katherine E. Pendleton, Benjamin G. Barwick, Renee Julia Manalo +12 more

Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

Leukemia(2022)10.1038/s41375-022-01711-0

N/A

0.529DataRank · unranked

33 citations

Vijai Joseph, Yolanda Benavente, Nicola J. Camp, Alexandra Nieters, Zhaoming Wang +95 more

Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients

Blood Cancer Journal(2020)10.1038/s41408-020-00382-3

N/A

0.520DataRank · unranked

31 citations

Kerstin Wenzl, Keenan T. Hartert, Michelle K. Manske, Vivekananda Sarangi, Matthew J. Maurer +10 more

Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL

Blood Cancer Journal(2024)10.1038/s41408-024-01080-0

N/A

0.385DataRank · unranked

12 citations

Matthew E. Stokes, Joseph P. Novak, Allison M. Bock, Sana Khan, Melissa A. Hopper +25 more

Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101443

N/A

0.373DataRank · unranked

11 citations

Kerstin Wenzl, Melissa A. Hopper, Michelle K. Manske, Vivekananda Sarangi, Matthew J. Maurer +16 more

PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma

Cancer Cell(2021)10.1016/j.ccell.2021.10.007

N/A

0.373DataRank · unranked

11 citations

Stephen M. Ansell, Patrizia Mondello

Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study

Blood Cancer Journal(2023)10.1038/s41408-023-00942-3

N/A

0.345DataRank · unranked

9 citations

Jennifer Gile, Melissa C. Larson, Kittika Poonsombudlert, Reema Tawfiq, Seth Maliske +14 more

Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphoma

Blood Cancer Journal(2025)10.1038/s41408-025-01326-5

N/A

0.322DataRank · unranked

7 citations

Kerstin Wenzl, Joseph P. Novak, Matthew E. Stokes, Melissa A. Hopper, Abigail R. Dropik +17 more

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma

Hematological Oncology(2022)10.1002/hon.3098

N/A

0.312DataRank · unranked

7 citations

Raphael Mwangi, Alexandra N. Smith, Matthew J. Maurer, Umar Farooq, Rebecca L. King +9 more

Molecular classification and identification of an aggressive signature in low‐grade B‐cell lymphomas

Hematological Oncology(2023)10.1002/hon.3187

N/A

0.269DataRank · unranked

5 citations

Kerstin Wenzl, Keenan T. Hartert, Jordan E. Krull, Abigail R. Dropik, Joseph P. Novak +16 more

Vaccination History and Risk of Lymphoma and Its Major Subtypes

Cancer Epidemiology Biomarkers & Prevention(2021)10.1158/1055-9965.epi-21-0383

N/A

0.241DataRank · unranked

4 citations

Melissa C. Larson, Stephen M. Ansell, Carrie A. Thompson, Grzegorz S. Nowakowski, Timothy G. Call +10 more

DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas

Blood Cancer Journal(2024)10.1038/s41408-024-01145-0

N/A

0.241DataRank · unranked

4 citations

Abigail R. Dropik, Janek S. Walker, Joseph P. Novak, M. Laverty, Michelle K. Manske +16 more

Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.17_suppl.lba7564

N/A

0.208DataRank · unranked

3 citations

Justin Kline, Aleksandr Lazaryan, Nancy L. Bartlett, Francisco J. Hernandez‐Ilizaliturri, Farrukh T. Awan +13 more

Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance

Hematological Oncology(2024)10.1002/hon.70006

N/A

0.208DataRank · unranked

3 citations

Kerstin Wenzl, Joseph P. Novak, Matthew E. Stokes, Melissa A. Hopper, Jordan E. Krull +17 more

Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

Blood Advances(2025)10.1182/bloodadvances.2025018079

N/A

0.208DataRank · unranked

3 citations

Sarah C. Rutherford, Stephen M. Ansell, Philippe Armand, John P. Leonard, Loretta J. Nastoupil +20 more

Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma

Cancer Research Communications(2024)10.1158/2767-9764.crc-24-0252

N/A

0.208DataRank · unranked

3 citations

Hsin-Hui Huang, Opeyemi A. Jagede, Kevin Tuballes, Diane M. Del Valle, Geoffrey Kelly +19 more

Anaplastic large cell lymphomas with equivocal DUSP22 FISH results: recommendations for clinical reporting and diagnostic evaluation

Human Pathology(2023)10.1016/j.humpath.2023.08.007

N/A

0.165DataRank · unranked

2 citations

Naoki Oishi, Min Shi, Surendra Dasari, Stephen M. Ansell, Rhett P. Ketterling +2 more

Prognostic relevance of CD4+ T-cells in the microenvironment of newly diagnosed follicular lymphoma (FL) patients is independent of the tumor gene expression profile.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8052

N/A

0.104DataRank · unranked

1 citations

Angelo Famà, Melissa C. Larson, Andew L. Feldman, Zhi-Zhang Yang, José C. Villasboas +13 more

Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival

Experimental Hematology and Oncology(2025)10.1186/s40164-025-00623-w

N/A

0.104DataRank · unranked

1 citations

Patrizia Mondello, Zixing Wang, Ying Li, Radhika Bansal, Sangeetha Gandhi +33 more

Expression of KLRG1 and CD127 defines distinct CD8+ subsets that differentially impact patient outcome in follicular lymphoma

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002662

N/A

0DataRank · unranked

39 citations

Xinyi Tang, Hyo Jin Kim, Shahrzad Jalali, Joshua C. Pritchett, José C. Villasboas +4 more

Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes

UNC Libraries(2020)10.17615/y5gv-3561

N/A

0DataRank · unranked

0 citations

Anneclaire J. De Roos, Brian K. Link, Anne J. Novak, Yuanqing Ye, Mitchell J. Machiela +95 more

Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

UNC Libraries(2024)10.17615/1b8m-w521

N/A

0DataRank · unranked

0 citations

Heather J. Sutherland, Paul Brennan, Laurie Burdett, Nicola J. Camp, Xiaosheng Wu +95 more

Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia

UNC Libraries(2024)10.17615/vsck-8v23

N/A

0DataRank · unranked

0 citations

N. Chatterjee, A. Maria, Lynn R. Goldin, Vijai Joseph, Sílvia de Sanjosé +76 more

Hypomagnesemia in Large B cell Lymphoma patients receiving CAR T cell therapy correlates with immune dysregulation and decreased PFS: results from the ZUMA-1 trial and Mayo Clinic cohort

Research Square(2024)10.21203/rs.3.rs-4889200/v1

N/A

0DataRank · unranked

0 citations

Patrizia Mondello, Zixing Wang, Ying Li, Radhika Bansal, Sangeetha Gandhi +33 more

Risk of lymphoid malignancy associated with cancer predisposition genes

Blood Cancer Journal(2025)10.1038/s41408-025-01283-z

N/A

0DataRank · unranked

8 citations

Raphael Mwangi, Dennis P. Robinson, Cristine Allmer, Allison Rosenthal, Thomas M. Habermann +95 more

A genome-wide association study of marginal zone lymphoma shows association to the HLA region

UNC Libraries(2020)10.17615/jztp-9s41

N/A

0DataRank · unranked

0 citations

Nikolaus Becker, Bengt Glimelius, Jian Gu, Brenda M. Birmann, Kari E. North +27 more

Evaluation of Etiologic Heterogeneity for Risk of Diffuse Large B-Cell Lymphoma Subtype Defined by the Cell of Origin

Cancer Epidemiology Biomarkers & Prevention(2025)10.1158/1055-9965.epi-24-1610

N/A

0DataRank · unranked

0 citations

Dennis P. Robinson, Lisa M. Rimsza, Melissa C. Larson, Rebecca L. King, Grzegorz S. Nowakowski +9 more

Predictors of Transplant Regret: A Case–Control Study Nested Within a Prospective Cohort of HSCT Recipients

Cancer Medicine(2025)10.1002/cam4.70828

N/A

0DataRank · unranked

0 citations

James R. Cerhan, William J. Hogan, Hannah Edwards, Christi A. Patten, Tabetha A. Brockman +6 more

83 | SINGLE CELL ANALYSIS REVEALS EXTENSIVE IMMUNE EXHAUSTION AND MEMORY‐CELL LIKE ORIGIN IN FOLLICULAR LYMPHOMA (FL) WITH INCREASED IRF4 EXPRESSION

Hematological Oncology(2025)10.1002/hon.70093_83

N/A

0DataRank · unranked

0 citations

Surendra Dasari, Vaishali Bhardwaj, Pinku Mukherjee, Xinyi Tang, Zhi-Zhang Yang +6 more

Cytokine-inducible SH2-containing protein (CISH) is an intracellular immune checkpoint that controls T regulatory cells in Splenic Marginal Zone Lymphoma 2122

The Journal of Immunology(2025)10.1093/jimmun/vkaf283.085

N/A

0DataRank · unranked

0 citations

Zhi-Zhang Yang, Yue Yu, Xiaosheng Wu, Vaishali Bhardwaj, Prithviraj Mukherjee +5 more

Investigating polyclonal Follicular Lymphoma tumors to determine the inciting factors for lymphomagenesis 4549

The Journal of Immunology(2025)10.1093/jimmun/vkaf283.2220

N/A

0DataRank · unranked

0 citations

Jordan E. Krull, Joe Novak, Abigail R. Dropik, Janek S. Walker, Kerstin Wenzl +8 more

Effect of antibiotic use prior to or concurrent with immune checkpoint inhibitors on outcomes in patients with Hodgkin lymphoma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8030

N/A

0DataRank · unranked

0 citations

Alexandra Higgins, Betsy LaPlant, Matthew J. Maurer, Stephen M. Ansell, Gita Thanarajasingam +2 more

Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell Therapy

Mayo Clinic Proceedings(2022)10.1016/j.mayocp.2022.05.018

N/A

0DataRank · unranked

30 citations

Janina Paula T. Sy‐Go, Jing Miao, Ramila A. Mehta, Lisa E. Vaughan, N. Nora Bennani +12 more

TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti–PD-1 Response in Follicular Lymphoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0558

N/A

0DataRank · unranked

116 citations

Hyo Jin Kim, Hongyan Wu, Shahrzad Jalali, Xinyi Tang, Jordan E. Krull +4 more

Secreted ORF8 is a pathogenic cause of severe COVID-19 and is potentially targetable with select NLRP3 inhibitors

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.12.02.470978

N/A

0DataRank · unranked

14 citations

Michelle K. Manske, Gordon Ruan, Taylor L. Witter, Kevin E. Nowakowski, Jithma P. Abeykoon +14 more

T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma

Blood Cancer Journal(2023)10.1038/s41408-023-00899-3

N/A

0DataRank · unranked

19 citations

Hyo Jin Kim, Hongyan Wu, Xinyi Tang, Yue Yu, Jordan E. Krull +13 more

Secreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in patients with severe COVID-19

iScience(2023)10.1016/j.isci.2023.106929

N/A

0DataRank · unranked

18 citations

Michelle K. Manske, Gordon Ruan, Taylor L. Witter, Kevin E. Nowakowski, Jithma P. Abeykoon +14 more

Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma

Blood Cancer Journal(2021)10.1038/s41408-020-00394-z

N/A

0DataRank · unranked

17 citations

Aung M. Tun, Yucai Wang, Thomas M. Habermann, Rebecca L. King, Kay M. Ristow +7 more

Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2023)10.1158/1078-0432.c.6531017.v1

N/A

0DataRank · unranked

0 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more

Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2023)10.1158/1078-0432.c.6531017

N/A

0DataRank · unranked

0 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more

Data from Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma

(2023)10.1158/1055-9965.c.6516286.v1

N/A

0DataRank · unranked

0 citations

Anne J. Novak, Zachary S. Fredericksen, Mark Liebow, Stephen M. Ansell, Ahmet Doǧan +8 more

The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T‐cell therapy

American Journal of Hematology(2021)10.1002/ajh.26313

N/A

0DataRank · unranked

32 citations

Radhika Bansal, Matthew Hathcock, Corina Doleski, Justin Hayne, Tuan Truong +8 more